Benefits of Centralized ECG Reading in Clinical Oncology Studies

Many clinical trials of investigational oncologic agents utilize electrocardiogram (ECG) machine measurements of QTc, for inclusion/exclusion and dosing decisions, though their reliability in this setting has not been established. However, this analysis of 270,000 ECGs from multiple oncology studies concluded that as many as 45% of the patients excluded due to prolonged QTc were actually eligible for enrollment when correctly evaluated through centralized ECG measurement.

Learn why reliance on ECG machine QTc measurements during clinical oncology trials may lead to unnecessary exclusion of patients as well as unneeded treatment interruptions.

Read the full article below, or download it here.

Therapeutic_Innovation___Regulatory_Science_2015_Kleiman_2168479015597729 (1)
Share